Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

0.8301 -0.0683 (-7.60%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 18, 2024

Via Benzinga

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

January 18, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday ↗

January 10, 2024

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.

Via Benzinga

Topics Stocks

What 6 Analyst Ratings Have To Say About Coherus BioSciences ↗

November 28, 2023

Via Benzinga

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces U.S. Launch of LOQTORZI™

January 02, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

December 29, 2023

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Via Benzinga

FLJ Group, Bit Digital And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

December 29, 2023

U.S. stock futures were slightly higher this morning, with the Dow Jones futures gaining around 15 points on Thursday. Shares of FLJ Group Limited(NASDAQ: FLJ) rose sharply in pre-market trading.

Via Benzinga

Topics Stocks

Why Coherus BioSciences Stock Jumped Today ↗

December 28, 2023

Coherus finally received FDA approval for its Udenyca OnBody injector system.

Via The Motley Fool

Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher ↗

December 27, 2023

U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Wednesday. The Dow traded up 0.05% to 37,564.54 while the NASDAQ fell 0.04% to 15,069.30. The...

Via Benzinga

Topics Stocks

Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 27, 2023

Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 27, 2023

Via Benzinga

Gold Gains 1%; Richmond Fed Manufacturing Index Falls In December ↗

December 27, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 80 points on Wednesday. The Dow traded up 0.22% to 37,626.76 while the NASDAQ rose 0.06% to 15,084.02. The S&P...

Via Benzinga

Topics Economy Stocks

Why Coherus BioSciences Stock Is Climbing Today ↗

December 27, 2023

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody.

Via Benzinga

US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY ↗

December 27, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while...

Via Benzinga

Topics Stocks

Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

December 27, 2023

Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal....

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 27, 2023

Via Benzinga

S&P 500, Nasdaq Set For Wobbly Open As Santa Claus Rally Fades: Analyst Sees Final Trading Sessions As 'Last Great Buying Opportunity' ↗

December 27, 2023

U.S. stocks may face challenges in maintaining their upward momentum on Wednesday, as index futures suggest a flat start. In the absence of significant catalysts, the market might experience a lack of...

Via Benzinga

Topics Stocks

Coherus BioSciences And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

December 27, 2023

U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday.

Via Benzinga

Topics Stocks

Coherus BioSciences, Ascent Industries And 3 Stocks To Watch Heading Into Wednesday ↗

December 27, 2023

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 26, 2023

Via Benzinga

Coherus BioSciences Stock Is Soaring After-Hours - Here's Why ↗

December 26, 2023

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher in Tuesday's after-hours session following the company's announcement of the U.S.

Via Benzinga

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

December 26, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street ↗

December 24, 2023

These two biotech stocks could be poised for a trend reversal.

Via The Motley Fool

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

December 11, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Announces CFO Transition Plans

December 07, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

December 06, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗

December 02, 2023

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...

Via Talk Markets

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical

November 28, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.